Biopharmx Corp (NYSEAMERICAN:BPMX) shares saw strong trading volume on Thursday . 25,619,400 shares traded hands during mid-day trading, an increase of 238% from the previous session’s volume of 7,581,873 shares.The stock last traded at $0.14 and had previously closed at $0.13.

Separately, Maxim Group reaffirmed a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a research note on Friday, December 8th.

The firm has a market cap of $14.93, a P/E ratio of -0.48 and a beta of 1.33.

Biopharmx (NYSEAMERICAN:BPMX) last announced its quarterly earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.05).

In other news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of Biopharmx stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Stephen Morlock purchased 330,000 shares of the business’s stock in a transaction dated Friday, November 24th. The shares were purchased at an average cost of $0.15 per share, for a total transaction of $49,500.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/01/18/biopharmx-bpmx-sees-large-volume-increase.html.

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.